January 2019 DAIDS Council-Approved Concepts

Concepts represent early planning stages for program announcements, requests for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements.

NB: Council approval does not guarantee that a concept will become an initiative.

Table of Contents

Fiscal Year 2020 Concept

Fiscal Year 2020 Small Business Innovation Research (SBIR) Contract Solicitation Topics

Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and Uninfected Individuals To Inform Innovative Tuberculosis Vaccine Design

Program Announcement With Special Receipt, Referral, and or Review Considerations—proposed FY 2020 initiative

Contact: Cesar Boggiano

Objective: This funding opportunity announcement (FOA) invites applications focusing on innovative studies to identify and understand the immunological responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or progression to active tuberculosis (TB) disease. Such responses may be operative in mycobacterial infection, or following vaccination with Bacillus Calmette-Guérin (BCG) or investigational vaccines. Studies may focus on any stage of mycobacterial infection and may include HIV-infected or -uninfected individuals. Research supported under this FOA should go beyond descriptive information currently known about Mtb infection, immune responses to TB vaccines, or immune modulation by non-tuberculous mycobacterial (NTM) infection or by HIV/AIDS. Applications are sought that include characterization of the timing, anatomical location, and contribution to disease outcome of mucosal and/or systemic immune responses to mycobacterial infection and/or vaccination. Examples of potential research areas include but are not limited to:

  • Elucidating mucosal and systemic adaptive immune responses, including signaling networks and regulatory mechanisms, throughout the course of mycobacterial infection/disease or vaccination and how HIV infection may shift this balance
  • Analyzing clinical trial samples evaluating TB vaccine candidates to identify immune correlates of protection from Mtb infection, or risk of TB disease progression
  • Analyzing innate immune pathways and mechanisms in response to Mtb infection and/or TB progression, including trained immunity and the effect on down-stream activation of adaptive immune responses
  • Applying systems immunology approaches for analyzing systemic and tissue-specific responses to Mtb, NTM, BCG, or investigational vaccines
  • Effect of prior/chronic exposure to mycobacterial species (including NTM) or BCG vaccination or other TB vaccine candidates on subsequent immune responses to Mtb infection, TB reactivation, or disease recurrence in HIV-infected or -uninfected individuals
  • Analyzing the role of non-classical T cells in immunity to Mtb infection
  • Determining the contribution of the humoral immune response to protection against Mtb
  • Identifying processes associated with mobilization/homing and maintenance of protective immune cells in the lung
  • Investigating the timing/nature of immune responses leading to protection against disseminated TB in children to determine whether activity of BCG can be modified to protect adults against Mtb infection or disease
  • Developing novel functional assays to monitor protective immune responses in humans

Note: Projects that use animal models, including the SIV/Mtb co-infection model, may be considered to address FOA objectives.

Description: The field of TB vaccine development has been hampered by a lack of opportunities to study novel and innovative questions addressing Mtb immunity and immune evasion in humans. This is because most immunological paradigms of host/pathogen interactions have been established in animals with limited validation in humans, providing limited insight into clinically relevant aspects of mycobacterial immunity and immune evasion such as spatial and temporal immune responses and their regulation. This initiative is designed to facilitate hypothesis-generating science in innovative, potentially dogma changing areas of TB vaccine design.

Small Molecule Targeting of HIV RNA

Note: NIAID topic for NIH SBIR contract solicitation.

Request for Proposals

Contact: Charles H. Jackson, Jr.

Sequence-Based Assays To Quantify the Replication-Competent HIV Reservoir

Note: NIAID topic for NIH SBIR contract solicitation.

Request for Proposals

Contact: Charles H. Jackson, Jr.

Content last reviewed on February 11, 2019